Clinical Trials Logo

Clinical Trial Summary

Anxiety and depression are normally associated with inflammation reactions and interleukin (IL) related pathways are most evidently involved. IL-17A (interleukin 17A) induces psoriasis-like inflammation and depression-like behaviors in animals and can be relieved by using IL-17A antibody. Also, human association studies found that IL-17A and certain downstream ILs are associated with the severity of anxiety. IL-17A is a sentinel cytokine. On binding with interleukin 17A receptor (IL-17RA) and interleukin 17C receptor (IL-27RC), it induces signaling cascades via nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB), P38 mitogen-activated protein kinases (p38MAPK) and CCAAT-enhancer-binding proteins (C/EBPs) knots, and stimulates subsequent cell secretions of cytokines and chemokines. Cyanidin 3-O-glucoside, the main anthocyanin component of mulberry, competes with IL-17A to bind its receptors and inhibits subsequent downstream cascades. The investigators plan to use a single-blinded randomized controlled trial to evaluate the auxiliary effect of mulberry juice in general anxiety disorder, including differences in psychiatric symptoms and levels of IL-related markers between the experimental and control groups, and contribution of IL-related genes in the auxiliary effect.


Clinical Trial Description

The etiology, pathogenesis, and pathophysiology of psychiatric disorders are not limited to the brain. Anxiety and depression are normally associated with inflammation reactions and interleukin (IL) related pathways are most evidently involved. Previous animal studies showed that administration of IL-17A induces psoriasis-like inflammation and depression-like behavior, and can be relieved by using IL-17A antibody, while in humans, association studies showed that serum IL-17A and certain downstream ILs are associated with the severity of anxiety. Also, the result of human genetic studies also identified several IL genes associated with anxiety and depression. IL-17A is a sentinel cytokine. On binding with interleukin 17A receptor (IL-17RA) and interleukin 17C receptor (IL-27RC), it induces signaling cascades via nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB), P38 mitogen-activated protein kinases (p38MAPK) and CCAAT-enhancer-binding proteins (C/EBPs) knots, and stimulates subsequent cell secretions of cytokines and chemokines. Many studies have demonstrated that consumption of proanthocyanidin-rich or anthocyanin-rich berries, berries juice or other secondary products reduce a variety of inflammation symptoms in humans. However, these berries do not meet a low-cost requirement for general nutritional recommendation and new drug development in Taiwan due to the additional import cost. On the other hand, cyanidin 3-O-glucoside, the main anthocyanin component of local mulberry, competes with IL-17A to bind its receptors and inhibits subsequent downstream cascades. Without interfering the on-going treatment of the patients, this proposal plans to use a single-blinded randomized controlled trial to evaluate the auxiliary effect of mulberry juice in general anxiety disorder, including differences in psychiatric symptoms (anxiety, depression, and functions) and levels of IL-related markers between the experimental and control groups, and contribution of IL-related genes in the auxiliary effect. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03935061
Study type Interventional
Source Taipei Medical University
Contact El-Wui Loh, PhD
Phone 886-2-22490088
Email lohew@hotmail.com
Status Recruiting
Phase N/A
Start date July 3, 2019
Completion date May 31, 2021

See also
  Status Clinical Trial Phase
Completed NCT00229034 - Effect of APC and Epo on the Inflammatory Response During Sepsis N/A
Completed NCT02051634 - Papaya Study ID:20140628 Phase 1
Not yet recruiting NCT06072066 - Effects of Oral Supplement Containing L-Histidine and Antioxidants on the Skin Barrier Function and Systemic Inflammation in Rosacea N/A
Recruiting NCT04769687 - Symbiotics and Systemic Inflammation in Chronic Kidney Disease Phase 2
Completed NCT01488500 - Woodsmoke Exposure and Cardiovascular Function N/A
Completed NCT01570062 - Cardiovascular Effects of Aerosols in Residences Study Phase 2
Completed NCT01256957 - Effect of HEPA Air Filters on Subclinical Markers of Cardiovascular Health N/A
Recruiting NCT03050476 - Preventing Systemic Inflammation After Cardiac Surgery With Alkaline Phosphatase Phase 2/Phase 3
Active, not recruiting NCT03442348 - Omega 3 and Fibre Intervention Study to Improve Metabolic Health N/A
Recruiting NCT03510442 - Natural History, Genetics, and Pathophysiology of Systemic Juvenile Idiopathic Arthritis, Adult-Onset Still's Disease, and Related Conditions
Withdrawn NCT01092572 - Statins To Treat Adult Cystic Fibrosis Phase 1/Phase 2
Enrolling by invitation NCT06322641 - A Study to Understand the Real-world Awareness and Perceptions of Systemic inFLAMmation and rolE of hsCRP as a Biomarker in Patients With AtheroSclerotic CardioVascular Disease and Chronic Kidney Disease Among Nephrologists
Completed NCT04314739 - The Effects of Resveratrol Supplementation on Inflammation and Cognitive Performance in Healthy Adults N/A
Completed NCT04728165 - Anti-Inflammatory Effects of Time-Restricted Feeding
Completed NCT03812627 - Study of Systemic Impact of Trace Elements Release by Implantable Medical Devices. Identification of Biomarkers of Systemic Inflammation N/A
Completed NCT00780520 - The Effect of Glutamine on Systemic Inflammation During Human Experimental Endotoxemia N/A
Enrolling by invitation NCT05350774 - Immunotherapy for Neurological Post-Acute Sequelae of SARS-CoV-2 Phase 2
Completed NCT00673907 - HIPWOODS - Health Effects Related to Exposure to Particle Pollution From Woodburning Stoves N/A
Completed NCT04161378 - Impact of Cardiac Rehabilitation Programs on Left Ventricular Remodeling After Acute Myocardial Infarction - the REHAB Trial
Completed NCT03448094 - The Effects of Resveratrol Supplementation on Cognition, Cerebral Blood Flow, Microbiota and Systemic Inflammation. N/A